Physician profile
Robert F Gray
NPI 1841203825
$1,486.72
in general payments reported to CMS, 2019-2025
10 companies · $177 in 2025
The $177 reported for 2025 was less than what a typical Otolaryngology/Facial Plastic Surgery provider received nationally (typical 2025 total: $305).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $507 · 2020: $229 · 2021: $36.07 · 2022: $39.81 · 2023: $182 · 2024: $316 · 2025: $177.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $656 · Education: $19.30.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $655.88 |
| Education | $19.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $431.06 | 2019-2021 | |
| Abbvie INC. | $361.04 | 2023-2025 | |
| Revance Therapeutics, INC. | $159.09 | 2024-2025 | Daxxify |
| Galderma Laboratories, L.P. | $146.00 | 2019 | |
| Merz North America, INC. | $125.00 | 2019 | |
| Stryker Corporation | $106.97 | 2021-2024 | Xpress Ent Dilation System, Essx |
| Acclarent, INC | $105.33 | 2020-2023 | Trudi Nav Cable |
| Polynovo North America LLC | $18.72 | 2024 | Novosorb Btm |
| Ucb, INC. | $17.35 | 2020 | |
| Janssen Biotech, INC. | $16.16 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Gray listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.